

AK

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72823 A1

- (51) International Patent Classification⁷: A61K 9/127 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/EP00/04783
- (22) International Filing Date: 25 May 2000 (25.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
199 24 313.1 27 May 1999 (27.05.1999) DE
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): EURO-CELTIQUE S.A. [LU/LU]; 122, Boulevard de la Petrusse, L-2230 Luxembourg (LU).
- Published:
— With international search report.
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): FLEISCHER, Wolfgang [DE/DE]; Posener Strasse 6, D-55218 Ingelheim (DE). REIMER, Karen [DE/DE]; Im Rehwinkel 12, D-65582 Hambach (DE).
- (48) Date of publication of this corrected version: 7 June 2001
- (15) Information about Correction:
see PCT Gazette No. 23/2001 of 7 June 2001, Section II
- (74) Agent: MAIWALD, Walter; Maiwald Patentanwalts-GmbH, Elisenhof, Elisenstrasse 3, D-80335 München (DE).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PREPARATIONS FOR THE APPLICATION OF ANTI-INFLAMMATORY AGENTS

(57) Abstract: Use of an anti-inflammatory agent, such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases in the interior of the human or animal body which are susceptible to the administration of such agents.

WO 00/72823 A1

5

PREPARATIONS FOR THE APPLICATION OF ANTI-INFLAMMATORY AGENTS

10 The invention concerns preparations for the application of agents with anti-inflammatory, especially antiseptic and/or wound healing promoting properties, to the interior of the human or animal body. The preparations are specifically applied to bones, organs, joints, muscle tissue, mucous membranes and mucosa-like unkeratinized epithelial tissues forming interior body parts of humans and animals.

15 Especially, the invention concerns the prevention or treatment of infections in joints such as the knee, the hip joint, the shoulder joint and the elbow.

Furthermore, the invention concerns a method of preventing or treating infections by applying a pharmaceutical preparation.

20

A plurality of different antibiotic and antiseptic agents are known for the topical treatment of infectious maladies. A decisive disadvantage of antibiotic agents is that the infecting bacteria show primary resistances, and can acquire secondary resistances, against these agents. Further, antibiotics quite often lead to patient

25 sensibilisation. The use of e.g. halogen-releasing antiseptics such as povidone iodine, also known as polyvidone iodine or PVP-iodine, i.e. the poly(1-vinyl-2-pyrrolidin-2-one)-iodine complex, can prevent resistances. Antiseptic agents are also much more rarely allergenic as compared to antibiotics.

30

A plurality of different antibiotic and antiseptic agents are known for the topical treatment of infectious maladies. A decisive disadvantage of antibiotic agents is that the infecting bacteria show primary resistances, and can acquire secondary resistances, against these agents. Further, antibiotics quite often lead to patient

- 2 -

sensibilisation. The use of e.g. halogen-releasing antiseptics such as povidone iodine, also known as polyvidone iodine or PVP iodine, i.e. the poly(1-vinyl-2-pyrrolidin-2-one)-iodine complex, can prevent resistances. Antiseptic agents are also much more rarely allergenic as compared to antibiotics.

5

At present, infectious diseases of the interior body parts are generally treated with antibiotics. This leads to the complications which are known to the skilled person. For example, patients suffering from chronic inflammation of joints, such as the knee or elbow, are often treated with antibiotics in order to alleviate the symptoms.

10

However, this often merely leads to resistances of the bacteria which are responsible for the symptoms. Many diseases are caused by viruses and against these, antibiotics are not effective. Such patients are not cured from the infections.

15

The use of antiseptic and/or wound-healing promoting agents for external application to humans and animals is disclosed in our earlier patent EP 0 639 373. Specifically, liposome preparations of PVP-iodine are shown therein to be topically applicable to the external parts of the eye. These preparations generally take the form of a cream, an ointment, a lotion, a gel or a drop formulation.

20

Liposomes are well-known drug carriers and therefore the application of medicaments in liposomal form has been subject of investigation for quite some time. An overview concerning (pulmonary) delivery of liposome encapsulated drugs (in asthma therapy) is provided by the review "Pulmonary delivery of liposomes" (H. Schreier, in "Journal of Controlled Release", 24, 1993, p.209-223). The

25

physicochemical characterization of liposome aerosols and also their therapeutic applications to the respiratory tract are shown therein. Drugs that have been investigated for pulmonary delivery via liposomes include, e.g. anti-cancer agents, peptides, enzymes, anti-asthmatic and anti-allergic compounds and, as mentioned above, also antibiotics. The formulation of liposome aerosols or liposome powder

30

aerosols using, for example a dry powder inhaler has also been described by H. Schreier in "Formulation and *in vitro* performance of liposome powder aerosols"

- 3 -

(S.T.P. Pharma Sciences 4, 1994, p.38-44).

Although, especially in the lower respiratory tract or for external application, some attention has been paid for quite some time to liposomes as drug carriers, there
5 appears to be no prior art relating to liposomes and other particulates as carriers of antiseptic or wound-healing promoting agents for applications in the interior of the body, especially in joints.

In fact, there appears to be a marked reluctance in the art, to apply disinfectants to
10 interior parts of the body, except maybe in extreme cases of life-threatening septical complications. Generally, antibiotic preparations appear to be preferred, even in view of their above-discussed disadvantages.

An object of the instant invention is to provide a well tolerated, easily applicable
15 antiseptic and/or wound-healing promoting preparation, which provides protracted release and protracted topical effect of the active agent in the body interior, especially in joints, such as the knee, the hip joint, the elbow, the shoulder joint etc.

According to the invention this object is attained in that the preparation comprises at
20 least one antiseptic and/or wound healing promoting agent in the form of a particulate carrier preparation, as defined in independent claim 1.

The invention further comprises a method of treating interior parts of the body, in humans and animals, as defined in independent claim 19.
25

The dependent claims define further advantageous embodiments of the invention.

The invention is premised on the surprising fact that particulate carriers, especially liposomes, are highly suited as carriers for antiseptic agents, especially for povidone
30 iodine, and for agents promoting the healing of wounds, for application to interior body parts, especially joints.

- 4 -

The preparations according to this invention permit protracted release of the agent or agents, and provide an extended and topical activity at the desired locus of action by interaction with cell surfaces.

5

In the context of the invention, the body interior is considered to broadly include those parts of the body which are enclosed by the skin, excluding the external skin areas and the cavities which are freely accessible from the outside, basically those leading from the mouth through the gastro-intestinal tract to the organs of excretion, and those leading from the nose into the lung.

10

In the context of the invention, anti-inflammatory agents are understood to include antiseptic agents, antibiotic agents, corticosteroids, and wound-healing agents, as defined below.

15

In the context of this invention, antiseptic agents are understood to include those disinfecting agents which are pharmaceutically acceptable and suitable for the treatment of the interior of the human or animal body to the extent that they can be formulated in accordance with the invention.

20

More specifically, antiseptic agents include *inter alia* oxygen- and halogen-releasing compounds; metal compounds, e.g. silver and mercury compounds; organic disinfectants including *inter alia* formaldehyde-releasing compounds, alcohols, phenols including alkyl- and arylphenols as well as halogenated phenols, quinolines and acridines, hexahydropyrimidines, quaternary ammonium compounds and iminium salts, and guanidines.

25

Wound-healing agents comprise agents promoting granulation and epithelization such as dexpanthenol, allantoines, azulenes, tannines, and vitamine B-type compounds.

30

- 5 -

The invention is, another aspect, based on a further surprising and unexpected fact. It is well known in the art that the formation of new body tissues may cause problems. Thus, it is known that body tissue repair may be accompanied by the formation of scar tissue, which can be functionally and/or cosmetically harmful, or at least undesirable. Hyperkeratosis and the uncontrolled proliferation of tissue may cause serious harm, leading to dysfunctions, and may of course also be cosmetically undesirable. After infections and inflammations, re-growing or healing tissue may cause neoplasms and intergrowth. It is thus well known in the art that in the curing of diseases, proper remodelling of tissue is not only desirable, but in fact necessary.

It has now been surprisingly found that the use of anti-inflammatory agents, singly or in combination with other such agents, leads to markedly less formation of undesirable body tissue in the course of tissue repair and other tissue growth processes. Thus, the formation of scar tissues is reduced, in skin but also in mucosa and in other tissues, such as muscle or inner organ tissues. Hyperkeratosis may be entirely suppressed, and intergrowth, or neoplasm formation in the curing of infective diseases is also highly reduced.

One object achieved by the invention is therefore concerned with improved tissue repair in the body. The invention achieves this by the application of anti-inflammatory agents, in the form of a particulate carrier preparation as defined in the independent claims.

The antiseptic or wound-healing preparation will generally be administered to the interior body part to be treated by invasive methods, especially by injection of the particulate carrier preparation, or by application of the respective preparation after a surgical step providing access to the locus of treatment. For example, a liposome preparation can be made by loading liposomes with PVP iodine in a conventional procedure. The nature or constitution of the liposomes are not critical. The liposome preparation as, for example, described in EP 0 639 373 can be administered by injection. The disclosure of EP 0 639 373 is incorporated by reference.

- 6 -

The preparations according to this invention apparently do not only contain the active agent, like povidone iodine, encapsulated in the particulate carrier, especially in liposomes. It seems that there is also some amount of agent which is not
5 contained inside the carrier. The preparations according to the invention often show a marked initial effect which is observed in addition to the slower, protracted release of the active agent from the carrier. This effect is especially observed where the carrier comprises liposomes. Without wishing to be bound to any theoretical explanation, it is presently assumed that in addition to active agent encapsulated
10 inside the liposomes, some active agent is present outside of the liposomes, and probably loosely bound to the outer surfaces of the liposomes. This could be due to association of active agent molecules with the liposomal membrane, or it could be due to active agent molecules forming a layer on the liposomal surface, which layer partly or even fully coats the liposome externally. The type and amount of this initial
15 agent effect can e.g. be influenced by choice of the concentration parameters.

Anti-inflammatory preparations according to this invention thus make it possible to achieve effects which cannot be provided by customary preparations.

20 Preferred antiseptic agents comprise the well-known pharmaceutical substances providing fast effect, a broad range of activity, low systemic toxicity and good tissue compatibility. They can e.g. be selected from the group comprising metal compounds, phenolic compounds, detergents, iodine and iodine complexes. A specifically preferred antiseptic agent is povidone iodine.

25 Preferred agents promoting the healing of wounds comprise substances which have been described in the literature for such application. Preferred such agents include substances known to promote epithelisation. These include vitamins, specifically from the vitamin B group, allantoin, some azulenes etc.

30

- 7 -

In preferred embodiments, the invention's preparations containing antiseptic and/or wound-healing promoting agents can comprise further agents such as anaesthetic agents. Inventive preparations can also contain customary further agents, including
5 adjuvants and additives, antioxidants, conserving agents or consistency-forming agents such as viscosity adjusting additives, emulgators etc.

The amphiphilic substances generally known in prior art to form liposome membranes can be employed in the context of the invention as long as they are
10 pharmaceutically acceptable for the intended application. Presently, liposome forming systems comprising lecithine are preferred. Such systems can comprise hydrogenated soy bean lecithine besides cholesterol and disodium succinate-hexahydrate; it is presently specifically preferred to use hydrogenated soy bean lecithine as the sole membrane forming agent.

15 The known prior art methods for forming liposome structures can generally be used in the context of the invention. Broadly, these methods comprise mechanical agitation of a suitable mixture containing the membrane forming substance and water or an aqueous solution. Filtration through suitable membranes is preferred in
20 forming a substantially uniform liposome size.

The size of the liposomes can vary over a broad range, generally from about 1 to about 20,000 nm. Liposomes with diameters between 50 and 4,000 nm are preferred and liposomes of up to approximately 1,000 nm diameter are presently most
25 preferred. For solutions, smaller average diameters may be more suitable.

Where alternative particulate carriers are used, they are generally prepared as known in the art. Thus, microspheres which are used to deliver a very wide range of therapeutic or cosmetic agents, are made as described for example in WO 95/15118.

30

Nanoparticles may in some cases be used, provided that they can be loaded with a

- 8 -

sufficient amount of active agent and can be administered according to this invention. They can be prepared according to the methods known in the art, as e.g. described by Heyder (GSF München) in "Drugs delivered to the lung, Abstracts IV, Hilton Head Island Conference, May 1998.

5

Methods using a pulse laser deposition (PLD) apparatus and a polymeric target to apply coatings to drug powders in a short non-aqueous process are also suitable for the formation of particulate preparations according to this invention. These have e.g. been described by Talton et al., "Novel Coating Method for Improved Dry Delivery", Univ. of Florida UF 1887 (1998).

10

A further suitable delivery system employs "Large Porous Particles" as disclosed by David A. Edwards et al. in "Large Porous Particles for Pulmonary Drug Delivery" (Science, 20. June 1997, Vol. 276, p. 1868-1871).

15

Generally, the concentrations in the preparation, particle sizes, active agent loadings etc. will be selected for such alternative carriers to correspond basically to the parameters discussed herein with respect to liposome preparations. Selecting and providing such parameter based *inter alia* on straightforward experimentation, is well within the skill of an ordinary worker experienced in this art.

20

A presently highly preferred use of the inventive liposome preparations is in the local treatment of infections of joints, such as the knee, hip, elbow and shoulder joints, especially when the liposome preparations contain povidone iodine. Also in this indication, the inventive antiseptic preparations, especially those containing PVP iodine, have the great advantage of not causing resistances and lead to much less allergic reactions, while permitting a very cost-efficient therapy with a broad spectrum of effect. A povidone iodine liposome preparation according to this invention is e.g. effective against viruses. This effect is not provided by antibiotic agents. Further, a liposome preparation of a microbicidal agent such as povidone iodine provides protracted release of the agent from liposomes. This leads to

25

30

- 9 -

extended effect of the antimicrobial substance, and thus less frequent application, as compared with the customary antiseptic solution preparations.

5 The present invention is also useful in the treatment of infectious diseases or for alleviation of diseases such as HIV infections which are accompanied by opportunistic infections. Also patients having a suppressed immune system, for example, after organ transplants, can be treated according to the invention. In particular, acute and chronic bronchitis, pneumonia, bronchiectasia, cystic fibrosis, diphtheria, tuberculosis can be treated with the povidone iodine preparation
10 according to the invention.

Another highly preferred use is in tissue repair, especially in functional and cosmetic tissue remodelling.

15 Preparations according to this invention can take a variety of forms, including solutions, dispersions, sprays and gels. Solid forms may sometimes be useful or even advantageous, but are generally less preferred than liquid forms.

Generally, the amount of active agents in an inventive preparation will be determined
20 by the desired effect, on the one hand, and the carrying capacity of the carrier preparation for the agent, on the other hand.

Broadly, a solution or dispersion of active agent in an inventive carrier preparation can range in concentration between the lower limit of effectiveness of the agent and
25 the solubility or dispersability limit of the agent in the respective solvent, dispersant, spray or gel.

More specifically, for an antiseptic such as povidone iodine, a solution or dispersion in an inventive carrier preparation, especially where the carrier is a liposome
30 preparation, can contain between 0.1 and 10 g of agent in 100 g of preparation. Such a preparation will then typically contain between 1 and 5 g of liposome membrane

- 10 -

forming substance, especially lecithine, per 100 g of preparation.

Especially preferred is an injectable preparation, which comprises up to 10 % povidone iodine (at 10 % iodine content) in a physiological saline liposome dispersion.

The features and advantages of this invention will become notable in more detail from the ensuing description of preferred embodiments. In these embodiments which include a best mode, povidone iodine is exemplified as an antiseptic agent and liposomes are chosen as the carrier. This should, however, not be construed as a restriction of this invention to antiseptic agents or, among antiseptic agents, to povidone iodine, and/or to liposomes as the carrier, although such preparations are specifically preferred.

One preferred method for producing the invention's liposomes can generally be described as follows:

The lipid membrane-forming components, e.g. lecithine, are dissolved in a suitable solvent such as chloroform or a 2:1 mixture of methanol and chloroform and are filtered under sterile conditions. Then, a lipid film is produced on a sterile high surface substrate, such as glass beads, by controlled evaporation of the solvent. In some cases, it can be quite sufficient to form the film on the inner surface of the vessel used in evaporating the solvent, without using a specific substrate to increase the surface.

An aqueous system is prepared from electrolyte components and the (one or more) active agents to be incorporated in the liposome preparation. Such an aqueous system can e.g. comprise 10 mmol/l sodium hydrogen phosphate and 0.9 % sodium chloride, at pH 7.4; the aqueous system will further comprise at least the desired amount of the active agent, which in the embodiment examples is povidone iodide. Often, the aqueous system will comprise an excess amount of agent or agents.

- 11 -

The liposomes are generally formed by agitating said aqueous system in the presence of said film formed by the lipid components. At this stage, further additives can be added to improve liposome formation; e.g. sodium cholate can be added. Liposome formation can also be influenced by mechanical action such as pressure filtration through e.g. polycarbonate membranes, or centrifuging. Generally, the raw liposome dispersion will be washed, e.g. with electrolyte solution as used in preparing the above-described solution of the active agent.

When liposomes with the required size distribution have been obtained and washed, they can be redispersed in an electrolyte solution as already described, often also comprising sugars such as saccharose or a suitable sugar substitute. The dispersion can be freeze-dried, and it can be lyophilised. It can, prior to use, be reconstituted by addition of water and suitable mechanical agitation at the transition temperature of the lipid component, which for hydrogenated soy bean lecithine is e.g. 55°C.

In the following Examples, hydrogenated soy bean lecithine (EPIKURON (TM) 200 SH obtainable from Lukas Meyer, Germany or PHOSPOLIPON (TM) 90 H obtainable from Nattermann Phospholipid GmbH, Germany) was used. However, other pharmaceutically acceptable liposome membrane forming substances can be used instead, and the person skilled in the art will find it easy to select suitable alternative liposome forming systems from what is described in prior art.

Embodiment Example I

In a 1000 ml glass flask, provided with glass beads for increased surface, 51.9 mg cholesterol and 213 mg hydrogenated soy bean lecithine were dissolved in a sufficient amount of a mixture of methanol and chloroform in a 2:1 ratio. The solvent was then evaporated under a vacuum until a film was formed on the inner surface of the flask and on the glass beads.

- 12 -

2.4 g PVP iodine (containing about 10 % available iodine) were separately dissolved in 12 ml water.

Again in a separate vessel, 8.77 g sodium chloride and 1.78 g $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ were dissolved in 400 ml water. Further water was added up to a total volume of 980 ml, and then, approximately 12 ml 1N hydrochloric acid were added to adjust pH to 7.4. This solution was then topped up with water to exactly 1000 ml.

In a fourth vessel, 900 mg saccharose and 57 mg disodium succinate were dissolved in 12 ml water.

The PVP iodine solution was then added to the lipid film in the flask and the mixture was shaken until the film dissolved. The resulting liposome formulation was separated from the hydrated lipids in the flask. The product was centrifuged and the supernatant liquid was discarded. The saccharose solution was added ad 12 ml and the product was again centrifuged. Afterwards the supernatant liquid was again discarded. At this stage, a further washing step, using the saccharose solution or the sodium chloride buffer solution could be used.

After the last centrifugation step and discarding of the supernatant, sodium chloride buffer solution was added ad 12 ml, and the liposomes were homogenously distributed therein. The product was then distributed into vials each containing 2 ml liposome dispersion, and the vials were then subjected to a freeze-drying step.

After the freeze-drying, each vial comprised about 40 mg solids.

The method of Embodiment Example I has a minor disadvantage in that the PVP iodine solution used, due to the high percentage of solids, is rather viscous and thus more difficult to handle.

- 13 -

Embodiment Example II

5 In a 2000 ml flask provided with glass beads to increase surface, 173 mg hydrogenated soy bean lecithine and 90 mg disodium succinate were dissolved in approximately 60 ml of a methanol/chloroform mix in a 2:1 ratio. The solvent was removed under vacuum until a film was formed.

10 4 g PVP iodine (10 % available iodine) were dissolved in 40 ml of the sodium chloride buffer solution described in Embodiment Example I, and were added to the lipid film in the flask. The flask was then shaken until the film dissolved and liposomes were formed.

15 The product was centrifuged and the supernatant liquid was discarded.

To the thus produced liposome pellet, further sodium chloride buffer solution was added ad 40 ml, and the centrifuging step was repeated. The supernatant was again discarded. At this stage, this washing step could be repeated where necessary.

20 After the final centrifuging and decanting step, sodium chloride buffer solution was again added to the precipitated liposomes ad 40 ml. The homogenous dispersion was then distributed into vials, each vial containing about 2 ml liposome dispersion, and the vials were then subjected to a freeze-drying step. This produced approximately 200 mg freeze-dried solids per vial.

25 From the freeze-dried solids of Examples I and II, further preparations were made as described in subsequent Embodiment Examples and Test Reports.

30 Like that of Embodiment Example I, the above-described method uses a hydrating step after film formation in the presence of organic solvents and aims at inclusion rates of 5 bis 15 %. These methods generally produce rather large and often multi-

- 14 -

lamellar liposomes.

The above-described methods can be modified by a high pressure filtering step through a suitable membrane such as a polycarbonate membrane after the raw liposomes have been formed or after any of the subsequent washing steps or directly
5 by using high pressure homogenisation. This produces much smaller, unilamellar liposomes at increased amounts of encapsulated agent.

Instead of high pressure homogenisation, other prior art methods known to provide
10 small uniform sized liposomes can be employed.

Embodiment Example III

An injectable dispersion was prepared from 10 g hydrogenated soy bean
15 lecithine/PVP iodine liposomes as described in Embodiment Example II; these were mixed with physiological saline ad 100 g.

Further modifications of the above-described embodiments are envisaged.

Thus, the dispersion of Embodiment Example III can have an additional content of
20 an agent known to promote the healing of wounds, such as allantoin. Such an agent will be added in a pharmaceutically useful concentration, in the case of allantoin in the range of 0.1 to 0.5 g, per 100 g of dispersion. The wound-healing agent can be incorporated in the saline, in which case it will largely be outside the liposomes. It
25 can, however, be partly or mostly incorporated in the liposomes, in which case it will be added at a corresponding suitable stage of the liposome preparation method.

It is also possible to prepare embodiments similar to the above described ones, which
comprise an agent capable of promoting the healing of wounds instead of, and not in
30 addition to, the antiseptic agent as e.g. povidone iodine disclosed in the above Embodiment Examples. Presently, it is however preferred to use a wound healing

- 15 -

promoting agent (if at all) in addition to an antiseptic agent.

Test I

5 This was an in-vitro-test of the bactericidal effect provided by an inventive povidone iodine liposome preparation. The test was based on the quantitative suspension test as described in "Richtlinien der Deutschen Gesellschaft für Hygiene und Mikrobiologie", 1989. In this test, the bactericidal agent is used to kill staphylococcus aureus (ATCC 29213), a major problem in hospital hygiene.

10

The liposome preparation used was that of Embodiment Example I. At different contact times between 1 und 120 minutes, the minimum concentration of the preparation in water was determined which was capable of killing the staphilococci.

15

The results are shown in Table 1.

TABLE I

	<u>Contact Time (Minutes)</u>	<u>Bactericidal Concentration</u>
	1, 2, 3, 4	$\geq 0.060 \%$
20	5, 30, 60	$\geq 0.015 \%$
	120	$\geq 0.007 \%$

The results show that at short contact times (between 1 and 4 minutes) the bactericidal concentration is as low as 0.06 % and that at long contact times (120 minutes) the bactericidal concentration can be as low as 0.007 %.

25

Test II

30 The virucidal and chlamydicidal activity of liposomal PVP-iodine has been studied, in cell cultures, by Wutzler et al., 9th European Congress for Clinic Microbiology and Infection Diseases, Berlin, March 1999. In cell cultures, liposomal PVP-iodine is

- 16 -

highly effective against herpes simplex virus type 1 and adenovirus type 8, while the long-term cytotoxicity experiments indicated that the liposomal form is better tolerated than aqueous PVP-iodine by the majority of cell lines tested. PVP-iodine in liposomal form is not genotoxic.

5

Test III

A 3% PVP-iodine hydrogel liposomal preparation was compared with a 3% PVP-iodine ointment, where the active agent was not in liposomal form. The agent was applied to standardized in vitro cultures of rat skin and peritoneal explants, as a screening for tissue compatibility of skin and wound antiinfectives.

10

The growth rate of the cultured explants was studied after 30 minutes exposure and incubation with a test substance.

15

Again, the substantially better toleration of the liposomal preparation was clearly shown in the results, in terms of peritoneum growth rate and skin growth rate.

20

With the ointment, the peritoneum growth rate reached 85%, and the skin growth rate reached 90%; with the liposomal hydrogel formulation, the peritoneum growth rate was 96%, and the skin growth rate was 108%; these values are to be compared with 100% values in a control test using Ringer's solution as the agent.

25

Test IV

In an unpublished study, the effects of povidone iodine in non-liposomal form was studied on adult articular cartilage.

30

Sesamoid bones were dissected within 2-4 h after slaughter from bovine metacarpophalangeal joints of adult animals under aseptic conditions. The cartilage from sesamoid bones of a particular animal is uniform with respect to glycosaminoglycan

- 17 -

synthesis, glycosaminoglycan content, and proteoglycan composition. Each experimental group consisted of eight sesamoid bones from the same animal. The sesamoid bones were washed in 10 ml cold sterile Ringer's solution for 10 min, incubated respectively in 10 ml of sterile Ringer's solution (control), PVP-iodine, or PVP-iodine dilutions with Ringer's solution (1:10, 1:100, or 1:1000) at 37°C for 10 min in a humidified atmosphere of 5 % CO₂ in air, and subsequently washed again for 5 x 5 min in 10 ml Ringer's solution in each case. After incubation of each pre-treated sesamoid bone for 24 h at 37°C in 10 ml Ham F-12 medium, supplemented with antibiotics, cartilage plugs of 2.8 mm in diameter were carefully removed and extracted thereafter in a stepwise manner. The culture media of sesamoid bones and extracts of cartilage plugs were used for the quantitative and qualitative characterization of proteoglycans and COMP (cartilage oligomeric matrix protein), because an increased release of fragments of these cartilage matrix constituents equals to a catabolic pathway.

10 min treatment of sesamoid bones with undiluted or diluted PVP-iodine induces no increased proteolytic fragmentation of investigated cartilage matrix constituents, compared with control experiments in Ringer's solution. That means there were no destructive activities in cartilage after the exposure to PVP-iodine.

This shows the desired tolerance of joint cartilage material to PVP-iodine even in non-liposomal form. As is known from the above reported other tests, liposomal preparations are even better tolerated than non-liposomal PVP-iodine preparations. Thus, the inventive liposomal or otherwise "carried" agent preparations would be expected to be evenly better tolerated as compared to the "uncarried" corresponding agent preparations.

- 18 -

Claims

1. A process for the manufacture of a pharmaceutical preparation for the application of anti-inflammatory, especially antiseptic agents and/or agents which promote the healing of wounds, to the interior of the human or animal body, **characterised in** that the preparation contains at least one of said agents combined with a particulate carrier.

2. The process of claim 1, **characterised in** that said particulate carrier comprises at least one of a liposome preparation, a microsphere preparation, a nanoparticle preparation, a Large Porous Particle preparation or a laser-pulse polymer coated molecule preparation.

3. The process according to claim 1 or 2, **characterised in** that at least the greatest part of said agent is encapsulated inside the carrier, especially a liposome or microsphere carrier.

4. The process of any one of claims 1 to 3, **characterised in** that the antiseptic agent is selected from oxygen- and halogen-releasing compounds; metal compounds, such as silver and mercury compounds; organic disinfectants including *inter alia* formaldehyde-releasing compounds, alcohols, phenols including alkyl- and arylphenols as well as halogenated phenols, quinolines and acridines, hexahydropyrimidines, quaternary ammonium compounds and iminium salts, and guanidines.

5. The process according to claim 4, **characterised in** that the antiseptic agent is selected from the group comprising metal compounds such as mercury compounds, phenol derivatives such as thymol, eugenol and hexachlorophene, iodine and iodine complexes.

6. The process according to claim 5,
characterised in that the antiseptic agent is povidone iodine.

7. The process according to any one of claims 1 to 6,
5 characterised in that the wound-healing promoting agent is selected from agents
promoting granulation and epithelization such as dexpanthenol, allantoines,
azulenes, tannines, compounds from the vitamin B series, or similarly acting agents.

8. The process according to any one of the preceding claims,
10 characterised in that the preparation contains at least one antiseptic and at least one
wound-healing promoting agent.

9. The process according to any one of the preceding claims,
characterised in that the carrier particles, especially liposomes, have a substantially
15 uniform size in the range between about 20 and about 20,000 nm, preferably in the
range between about 50 and about 4,000 nm, more preferably between 500 and 2,500
nm and especially preferably a uniform size of up to about 1,000 nm diameter.

10. The process according to any one of the preceding claims,
20 characterised in that the carrier, especially liposome, preparation releases the agent
over an extended time period, preferably an extended time period of several hours
duration.

11. The process according to claim 10,
25 characterised in that the carrier, especially liposome, preparation releases the agent
at approximately the same release rate over the release time period.

12. The process according to any one of the preceding claims,
characterised in that the preparation additionally comprises at least one
30 anaesthetically active agent.

13. The process according to any one of the preceding claims, characterised in that the preparation contains additives and adjuvants such as conserving agents, antioxidants and consistency-forming additives.

5 14. The process according to any one of claims 1 to 13, the preparation being in the form of a solution or dispersion comprising the active-agent loaded carrier, especially in the form of liposomes, preferably in the form of a liquid pharmaceutical preparation.

10 15. The process according to any one of the preceding claims, the preparation being in the form of a pharmaceutical solution or dispersion formulation, which comprises:

a) liposomes comprising a pharmaceutically acceptable liposome membrane forming substance; and

15 b) a 0.1 to 2 % PVP iodine solution (at approximately 10 % available iodine in the PVP iodine complex) at least most of which is encapsulated by said liposome membranes,
wherein the liposomes are of substantially uniform size between about 50 and about 4,000 nm, and, in case, the formulation additionally comprises customary additives,
20 adjuvants and auxiliary substances of a pharmaceutical solution or dispersion formulation.

16. The process according to claim 15, characterised in that the liposomes are of substantially uniform size, with diameters
25 at up to 1,000 nm.

17. The process according to any one of claims 1 to 16, wherein the preparation is suited for the treatment of infectious diseases or alleviation of diseases such as HIV infections which are accompanied by opportunistic infections or a
30 suppressed immune system.

- 21 -

18. The process according to any one of claims 1 to 16, wherein the preparation is suited for the treatment of acute and chronic infections of joints, especially the knee, hip, elbow and shoulder joints.

5

19. The process according to any one of claims 1 to 18, wherein the preparation is suited for functional and cosmetic tissue remodelling and repair treatments.

10

20. A method of preventing or treating infections of interior parts of the human or animal body, by applying, to said body part, a pharmaceutical preparation comprising at least one antiseptic agent and/or wound-healing promoting agent, said agent being combined with a particulate carrier in said preparation.

15

21. A method of functional and cosmetic tissue remodelling and repair of interior parts of the human or animal body, by applying, to said body part, a pharmaceutical preparation comprising at least one antiseptic agent and/or wound-healing promoting agent, said agent being combined with a particulate carrier.

20

22. The method of claims 20 or 21, wherein said carrier comprises at least one of a liposome preparation, a microsphere preparation, a nanoparticle preparation, a large Porous Particle preparation or a laser-pulse polymer coated molecule preparation.

25

23. The method of claims 20 or 21, wherein at least the greatest part of said agent is encapsulated inside the carrier, especially a liposome or microsphere carrier.

30

24. The method of claims 20 or 21, wherein the anti-inflammatory agent is selected from antiseptic agents, antibiotics, corticosteroids and wound-healing promoting agents.

- 22 -

25. The method of claims 20 or 21, wherein the antiseptic agent is selected from oxygen- and halogen-releasing compounds; metal compounds, such as silver and mercury compounds; organic disinfectants including *inter alia* formaldehyde-releasing compounds, alcohols, phenols including alkyl- and arylphenols as well as halogenated phenols, quinolines and acridines, hexahydropyrimidines, quaternary ammonium compounds and iminium salts, and guanidines.

26. The method of claims 20 or 21, wherein the antiseptic agent is selected from the group comprising metal compounds such as mercury compounds phenol derivatives such as thymol, eugenol and hexachlorophene, iodine and iodine complexes.

27. The method of claims 20 or 21, wherein the antiseptic agent is povidone iodine.

28. The method of claims 20 or 21, wherein the wound-healing promoting agent is selected from agents promoting granulation and epithelization such as dexpanthenol, allantoines, azulenes, tannines, compounds from the vitamin B series or similarly acting agents.

29. The method of claims 20 or 21, wherein the preparation contains at least one antiseptic and at least one wound-healing promoting agent.

30. The method of claims 20 or 21, wherein the carrier particles, especially liposomes, have a substantially uniform size in the range between about 20 and about 20,000 nm, preferably in the range between about 50 and about 4,000 nm, more preferably between 500 and 2,500 nm and especially preferably a uniform size of about 1,000 nm diameter.

- 23 -

31. The method of claims 20 or 21, wherein the carrier, especially liposome, preparation releases the agent over an extended time period, preferably an extended time period of several hours duration.

32. The method of claims 20 or 21, wherein the carrier, especially liposome, preparation releases the agent at approximately the same release rate over the release time period.

33. The method of claims 20 or 21, wherein the preparation additionally comprises at least one anaesthetically active agent.

34. The method of claims 20 or 21, wherein the preparation contains additives and adjuvants such as conserving agents, antioxidants and consistency-forming additives.

35. The method of claims 20 or 21, the preparation being in the form of a solution or dispersion comprising the active-agent loaded carrier, especially in the form of liposomes, preferably in the form of an injectable physiological saline pharmaceutical preparation.

36. The method of claims 20 or 21, the preparation being in the form of an injectable pharmaceutical solution or dispersion formulation, which comprises:

a) liposomes comprising a pharmaceutically acceptable liposome membrane forming substance; and

b) a 0.1 to 2 % PVP iodine solution (at approximately 10 % available iodine in the PVP iodine complex) at least most of which is encapsulated by said liposome membranes,
wherein the liposomes are of substantially uniform size between about 50 and about 4,000 nm, and, in case, the formulation additionally comprises customary additives, adjuvants and auxiliary substances of a pharmaceutical solution or dispersion

- 24 -

formulation.

37. The method of claim 36, wherein the liposomes are of substantially uniform size, with diameters at up to 1,000 nm.

5

38. The method of claims 20 or 21, wherein the preparation is suited for the treatment of infectious diseases or alleviation of diseases such as HIV infections which are accompanied by opportunistic infections or a suppressed immune system.

10

39. The method of claims 20 or 21, wherein the preparation is suited for the treatment of acute and chronic infections of joints, especially the knee, hip, elbow and shoulder joints.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/04783

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 639 373 A (EUROCELTIQUE) 22 February 1995 (1995-02-22) claims 1-12,14,17,18	1-17, 20-37
X	WO 96 14083 A (POLYMN SCIENTIFIC IMMUNOBIOLOGISCHE FORSCHUNG) 17 May 1996 (1996-05-17) claims 1,6,10,11,15	1-3,7, 9-11,13, 14, 17-24, 28, 30-32, 34,35, 38,39
P,X	WO 99 60998 A (EUROCELTIQUE) 2 December 1999 (1999-12-02) claims 1-47	1-17, 20-38



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 October 2000

Date of mailing of the international search report

27/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/04783

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 639373 A	22-02-1995	DE 9312509 U	28-10-1993
		AT 173917 T	15-12-1998
		DE 69414936 D	14-01-1999
		DE 69414936 T	12-08-1999
		ES 2124822 T	16-02-1999
		GR 3029436 T	28-05-1999
		JP 7145081 A	06-06-1995
		SI 639373 T	30-04-1999
		US 5863556 A	26-01-1999
WO 9614083 A	17-05-1996	AU 690377 B	23-04-1998
		AU 3981695 A	31-05-1996
		BR 9509590 A	23-12-1997
		CA 2204493 A	17-05-1996
		EP 0789584 A	20-08-1997
		US 5942245 A	24-08-1999
WO 9960998 A	02-12-1999	AU 4266799 A	13-12-1999
		AU 4370499 A	13-12-1999
		AU 4370699 A	13-12-1999
		WO 9961003 A	02-12-1999
		WO 9960999 A	02-12-1999